Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases
Overview
This Gastro Bites session is your exclusive opportunity to get insight and ask questions from the authors of the recent AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases — the first comprehensive guideline on the use of fecal microbiota-based therapies in GI diseases.
Fecal microbiota–based therapies include conventional fecal microbiota transplant and U.S. Food and Drug Administration–approved therapies, fecal microbiota live-jslm and fecal microbiota spores live-brpk. AGA’s guideline provides clinicians with recommendations on the use of fecal microbiota–based therapies in adults with recurrent Clostridioides difficile (C. diff) infection; severe to fulminant C. diff infection; inflammatory bowel diseases, including pouchitis; and irritable bowel syndrome.
Learning objectives
Guideline authors will share best practices and discuss:
- Fecal microbiota–based therapies to prevent recurrent C. diff in select patients.
- Conventional fecal microbiota transplant treatment for select adults hospitalized with severe or fulminant C. diff infection not responding to standard-of-care antibiotics.
- Refraining from recommending fecal microbiota transplants for gastrointestinal conditions.
Key dates
- Released date:
- Jul 23, 2024
- Expiration date:
- Jul 25, 2026
Pricing
Agenda
All times are Eastern.
Session Heading 1: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Session Heading 2: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Course contents
Video
30 mins
Evaluation
Course Faculty
Speaker
Colleen R. Kelly, MD
Member of the Faculty, Department of Medicine Brigham and Women’s Hospital
Byron P. Vaughn, MD, MS, AGAF
Associate Professor of Medicine Co-director, Inflammatory Bowel Disease Program Division of Gastroenterology, Hepatology, and Nutrition University of Minnesota
Dina Kao, MD, FRCPC
Professor of Medicine Director, Edmonton FMT program Division of Gastroenterology University of Alberta